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Advanced heart failure is characterized by allcmtions in 
vascular tone and response that may further cumpromiae 
perfusion. organ function and survival. The sympathetic 
nervous system, the renin-angiotensin system, natriuretic 
peptides, &opressin and cytokines can all influence wscu- 
lar tone under certain conditions. Originally regaoed as part 
of the audience, the endothelium has recently been recog- 
uized to participate actively in this choir thmugh synthesis 
and release of relaxing factors, prostagkmdins and endothe- 
lin (Fig. I). 
Pb&&gir eRects of endoihelin and endothelin receptors. 
Endotbelin. a 21.amino acid oeotide first described bv Yan- 
agisawa et ‘al, (I), is the modt pc:,ot vusoconstricti~g sub- 
stance known for the wcular smooth muscle of both 
arteries and veins. Of the three endothelins described, 
endathelin-I has been the best characterized (2). Stimuli for 
release from endothelial cells include norepinephrine, vasu- 
presrin, thrombin, transforming growth factor beta and 
interleukin-I. Renulation is orimarilv at the level of messaae 
transcrip:ion, ani the rest&tory &ion of human prepro& 
dotbelin-1 gene has been shown to contain sequences influ- 
enced by other acUe phase reactants. Release and cleavage 
of the big endothelin to active endothelin may be further 
sites of regulation. 
Endothelin receptors have been found in the heart and 
kidney as well as blood vessels. There are at least two 
receptor types for endotbelin (2). Endothelin-A receptors are 
oo smooth muscle cells. Endothelin mobilizes intracellular 
calcium release, stimulated by inositol triphosphate. Extra- 
cellular calcium entry contributes to the more sustained 
contractions. Voltage-dependent calcium channels are in- 
valved and adenosine triphosphate (ATPI-senaitivc potas- 
sium channels also may be stimulated by endotbelin (3). 
Through endothelin-B receptors on endothelial cells, phos- 
pholipare AZ is stimulated and the vasodilator prostacyelin is 
synthesized. These two endothelin actions cause the bipha- 
sic respmse that coo be seen after exogenous administration 
in animals. The initial brief vasodilator component appears 
to result from endothelin stimulation of prostacyclin produc- 
tion and can be blocked by cyclooxygenase inhibitors. The 
subsequent prolonged vasoconstriction can function to con- 
serve blood How to the hear, and brain, at the expense of the 
kidney and liver. 
Isolation of physiologic effects of endothelin in viva is 
complicated. In addition to direct vascular effects, endotbe- 
lin cau act in concert with other regulatory systems. Infu- 
sions in dogs can increase circulating levels of atrial natti- 
uretic factor, vasapressin and aldosterone (4). Rain release 
has been vatiously found to be stimulated or depressed (5,6), 
which may depend in pan on the degree of concomitant 
atrial natriuretic factor stimulation. Aldostemne appears to 
be directly stimulated thmugb endothelin receptors on the 
zona glomemlosa. These other regulatory systems also CM 
effect endotbelin action, because angiotensin II, vwpressin 
and endotbelin itself downregulate the endothelin-A recep- 
tors on smooth muscle cells (3). Clearance of eudothelin may 
vary among animals and among disease states. Whereas 
endothelin is cleared predominantly in the bmgs of rats (7). it 
is cleared through both the lungs and the kidneys of dogs. In 
a dog study of pacmg-inducea heart failure, baseline endo- 
thelin levels were elevated threefold and exogeuous admin- 
istration of endothelin to dogs with heart failure caused a 
greater increment in endothelin concentration but less effect 
on vasoconsiriction and renal blood Row than in control dogs 
(4). 
Rule uf increased end&h&n in dkase states. The co&- 
bution of endothelin to the human circulation has not been 
established. In normal volunteers, detectable levels of en- 
dothelin circulate normally. increase with upright tilting and 
cold exposure and decrease after saline infusion in parallel 
with plasma renin activity (S-IO). The cur :ut study by 
Lemmn et al. (I I) demonstrated atwofold increase in plasma 
endothelin-I levels in patients with class III and IV heart 
failure. Simultaneous studies of other patients with heart 
failure contino significant elevations compared with levels in 
normal control subjects: however, normai levels have varied 
almost threefold from study to study, and this variation may 
reflect differences in sampling site as well us variations io the 
specificity of the endothelin antibodies employed for the 
radioimrounoassay (S-13). The degree of elevation of plasma 
endothelin level in patients with heart failure mnges from 
twofold, as reported by Lerman et al. (1 I) and by MeMurray 
et al. (13) and Cody et al. (121, to fivefold, as reported by 
Stewart et al. (8). Patients whose beat failure was associ- 
ated with pulmonary hypertension had higher levels than 
those of other patients with heart failure (12). Elevated 
Fiin 1. Voices in Ik “*SC”,ar 
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wch as that from norepinephrine 
and an@otensin II. which directly 
stimulate contraction but also crius5 
down-regulation of endathelin re- 
ceptor A (ErA) receptors. ANF = 
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calcium $5”: cAMP = cyclic aden- 
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endalhelin levels have also been found in patients with 
primary pulmonary hypertension (14) and in patients with 
pulmonary hypertension secondary to congenital heart dis- 
ease (IS). Other cofiditions that have been associated with 
elevated endatheliu levels are acute myocardial infarction 
(16.17) and abdominal surgery (18). 
This study also demonstrates that endothelin levels are 
elevated after heart transplantation. Cyclosporine given at 
high doses to rats caused increased endothelin levels and 
renal dysfunction that could be prevented by administration 
,-F anti-endothelin antibodies (19). Cyclosp+ne also rcsult~ 
in an increase in sympathetic nerve traffic in humans. which 
could stimulate increased endothelin release (20). The differ- 
ences between findings in the current study of 8 patients and 
lhose of the study of Edwards et al. (21). in which 24 heart 
transplattl patients with and without cyclosporine therapy 
had normal endothelin levels, remain unexplained. The 
elevated endothelin kvels seen early alla hean ttansplan- 
tation may reflect the general stress of surgery, because high 
endothelin levels have been found after major abdominal 
surgery (18). At extended periods after transplantation. a 
greater degree of hypertention and renal dysfunction may 
have contributed to elevated levels in tne eument studjj. 
Role of endolbelbt itt heart failure. The results of this 
study surges: that cndotheli~ nay contribute to the circula- 
tory det&gentent of heart failure: However, detected levels 
of circulating endothelin may not necessarily indicate the 
physiologic contribution of this hormone. “Big” endothelin, 
which is inactive until converted, is recognized in most 
assays, which will thus overestimate the active endothelir.. 
The cross-reactivity of the antibody in this study was <37% 
with bigendathelin. Thespecilic’kndwich” immunoassags 
performed by Miyauchi et al. (17) showed active endotbe- 
lin-l levels to be in the range of I pglml, which is lower than 
that reported in less specific assays, and showed big endo. 
thelin t(i ‘k nunttaiiy present at twice the concentration of 
endothelin-I. In disease states the conversion of big endo- 
thelin could conceivably be imp&d so that more inactive 
hormone would be detected. The amount of wlease into the 
circulation kom the ettdothelium may be a small :raction of 
the active endothclin released abluminally to the smooth 
muscle cells, representing a “spillover” analogous to that of 
norepinephrine From sympathetic nerve terminals. Impaired 
pulmonary and renal clearance of endothelin, which might 
be expected in congestive states, may elevate levels despite 
normal local release. In addition, the effect of elevated 
endothelin levels can be reduced by downregulation of 
endothelin receptors (2). In the paced dog with heart failure, 
exogenous endathelin caused less systemic and renal vase- 
constriction than in the control dcg (4). 
What is the significance of endothelin elevation in heart 
failure? In this study, there were no cortG!ions between 
hemndynamic variables and the degree of elevkm, which 
was also reported by Cody et al. 112). However in the 
patients studied by Cody etal. (12). the level of endothelin 
elevation did not correlate with systemic vascular resistance 
M cardiac output in human heart failure, but it did reflect the 
degree of eler-,tios of intracardiac 8lling pressures. which 
has kee suggested to be the most critical hemcdynamic 
variable for both clinical function and prognosis once ad- 
vanced heart failure is present (22,23). Does endolhelin 
elevation represent a cause or an effect of decompensation? 
It has been shown tb&t coovarable levels may cause modest 
systemic vaeocoustriction in normal co&l patients. In 
the study of Vierhapper et al. (24), doses between 1 and 
2.5 nglkg per min resulted in levels of 10 to 20 p&/ml, which 
elevated mean arterial pressure by 4 mm Hg, but even higher 
doses did not cause cbao8es in plasma renin, aldosterone or 
atri~l natriuretic factor. Kiowrki et al. (25) demonstrated 
that very low doses caused forearm vasodilation, whereas 25 
to SO n&in per IW ml foream tissue increased local 
vascular resistance. It is not easy to determine what levels 
are relevant to pathophysiologic conditions because local 
release could cause concentrations many times higher than 
those circulating. However, when baseline endothelin levels 
are elevated, as in heart failure, the response to further 
endothelin elevations cat be blunted (4). It is not known to 
what extent inhibition of endothelin activity z;:: &iesti:i 
improve hcmodynamic status. Although the vasoconstrictor 
a&on of end&helium in viva may b; inhibited by calcium 
channel blocking agents (25). these agents have not provided 
major benefit in heart failure. It may be that any hemody- 
namic benefits of endothelin inhibition will be for reversal of 
secondary pulmonary hypertension or for preservation of 
threatened renal function, rather than for systemic vasodi- 
k&n. 
Lcng-term eUectr of endothelin. More intriguing than the 
potential for direct vasodilation is the possibility that endo- 
thelin may have more long-term effects on both the heart 
itself and the neurohumoml activation that appears to con- 
tribute to the progression of heart failure. Progression of 
earlv lelt ventricular dvsfunction has now been shown to be 
d&eased by angiot;nsin-converting enzyme inhibitors 
(26.27). Endothclin messenger ibonucleic acid (mRNA) has 
been demoustrated in human cardiac tissue. and anti- 
endothelin antibodies have iimiicd infarct size in SI rat model 
(28). Ooze hemodynamic ompromise at rest has developed, 
therapy for heart failure has been most effective when 
hcmodynamic improvement can be combined with inhibition 
of neurohumoml stimulation (29). In normal patients during 
infusion cd endothelin, remn, aldosterone and atrid natr- 
uretic factor levels were not altered (24). However, in dogs 
with pacing-induced heart failure, endothelin decreased 
plasma renin activity (4). Blockade of endothelin thus could 
be deleterious, advantageous or of no obvious el%ct, de- 
pending on the role of endothelin in the neurohumoral axis of 
patients with hart failure. 
Conctuslons. The studies of endothelin in patients, such 
as reported in this issue of the Journal. are critical for the 
demonstration that endothclin is abnormal in heart failure 
and after heart transplatation. Eodothelin has taken its 
place as another voice among the growing choir of circula- 
tory reguiaiion. Iiulhr: in,:c;:igalion will be directed to 
determine whether this elevation represents a true increase 
in endothclin activity, causes significant regional or systemic 
vasoconstriction and represents an adaptive or a deleterious 
response in these disease states. Such inw%tiga!ion wi!! 
ultimately detemune whether intervention directed against 
endothelin production and action will provide a new option 
for therapy of the abnormal circularion. 
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